Literature DB >> 1633038

Iliac artery stenting--clinical experience with the Palmaz stent, Wallstent, and Strecker stent.

K A Hausegger1, J Lammer, B Hagen, F Flückiger, M Lafer, G E Klein, E Pilger.   

Abstract

A total of 82 iliac artery lesions (62 stenoses and 20 occlusions) were treated with 3 different types of endovascular metallic stents (12 lesions with the Palmaz stent, 36 with the Wallstent, and 34 with the Strecker stent). The complication rate was 12%. Occlusion of 2 Wallstents occurred 4 and 12 weeks after stent placement, respectively. Both stents were recanalized by local fibrinolysis. One Strecker stent occluded after 8 months. The observation period was 3 to 26 months (mean 9.7 months). The patency rate with secondary intervention (fibrinolysis) was 100% after 3 and 6 months, and 98% after 9 months. All 3 stent designs turned out to be effective in the treatment of complicated iliac artery occlusive disease.

Entities:  

Mesh:

Year:  1992        PMID: 1633038

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  4 in total

Review 1.  Classical and endovascular surgery: indications and outcomes.

Authors:  E B Diethrich
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

2.  Comparison of a new stent and Wallstent for transjugular intrahepatic portosystemic shunt in a porcine model.

Authors:  G J Teng; M A Bettmann; P J Hoopes; L Yang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  Successful exclusion of a large femoropopliteal aneurysm with a covered nitinol stent.

Authors:  R Dorffner; F Winkelbauer; J Kettenbach; M Staudacher; J Lammer
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Mar-Apr       Impact factor: 2.740

4.  Predictors of primary patency failure in Wallstent self-expanding endovascular prostheses for iliofemoral occlusive disease.

Authors:  S Damaraju; L Cuasay; D Le; N Strickman; Z Krajcer
Journal:  Tex Heart Inst J       Date:  1997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.